"As we move forward, we intend to select Boke's most promising and profitable products to leverage across our large distribution network. We see the opportunity to further strengthen Boke's product line, improve operating efficiency, and maximize pricing for their leading products. We are eager to integrate our latest acquisition into AOBO's corporate culture and look forward to their many contributions to our business in the years to come," concluded Liu.
The monetary exchange rate used for this transaction is US$1.00 : RMB 7.51.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering is a leading, fully integrated, plant based pharmaceutical and plant based nutraceutical company dedicated to improving health through the development, manufacture and commercialization of modernized plant based products in China.
Safe Harbor Statement
This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts. These
statements are subject to uncertainties and risks including, but not
limited to, product and service demand and acceptance, changes in
technology, economic conditions, the impact of competition and pricing,
government regulation, and other risks contained in reports filed by the
Company with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether made by or
on behalf of the company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. In addition,
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2007 PR Newswire.
All rights reserved